MANGOCEUTICALS INC
MGRXNASDAQTrading Snapshot
- Day Range
- $0.44 – $0.45
- 52-Week Range
- $0.16 – $2.75
- Volume
- $5.20B
- Avg Volume
- $4.80B
- Shares Outstanding
- 17.2M
- Next Earnings
- Nov 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $456,021
- Last Q Revenue
- $68,757
- P/E Ratio
- —
- P/S Ratio
- 31.9x
- EPS (TTM)
- $-1.14
- Dividend Yield
- —
- Dilution (1yr)
- +389.5%
Why Investors Own MGRX
- ✓High-growth profile — revenue up +47.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 73% gross margin and 28% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
MANGOCEUTICALS INC
MGRX
StockOtter · stockotter.spaceAbout MANGOCEUTICALS INC
Mangoceuticals, Inc. dedicates its operations to the creation, promotion, and distribution of a variety of health and wellness products and services specifically designed for men. These offerings are primarily delivered through a telemedicine platform. The company's product line includes treatments for erectile dysfunction, marketed under the 'Mango' brand. Consumers can purchase these items directly from its official online portal, mangorx.com. Established in 2021, Mangoceuticals, Inc. is headquartered in Dallas, Texas, and operates as an affiliate of Cohen Enterprises, Inc.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Head to Head Survey: Mangoceuticals (NASDAQ:MGRX) and Chemed (NYSE:CHE)
Chemed (NYSE: CHE - Get Free Report) and Mangoceuticals (NASDAQ: MGRX - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of th
Analyzing Mangoceuticals (NASDAQ:MGRX) and LifeStance Health Group (NASDAQ:LFST)
LifeStance Health Group (NASDAQ: LFST - Get Free Report) and Mangoceuticals (NASDAQ: MGRX - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on
MGRX Stock Alert: Halper Sadeh LLC is Investigating Whether Mangoceuticals, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Mangoceuticals, Inc. (NASDAQ: MGRX) and Nuclea Energy Inc. Halper Sadeh encourages Mangoceuticals shareholders to c
Mangoceuticals Inc.'s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets
The acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department of Energy. Asset-led transaction to ad
Nuclea Energy, Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets
The acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department of Energy. Asset-led transaction to ad
Nuclea Energy Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure
The MOU will assess the technical feasibility of integrating Nuclea's modular reactor technology into New Mining's data center operations, with a phased evaluation path toward a cumulative 100 MWe of behind-the-meter cap